Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
AMARQ > SEC Filings for AMARQ > Form 10-K on 15-Apr-2014All Recent SEC Filings

Show all filings for AMARILLO BIOSCIENCES INC

Form 10-K for AMARILLO BIOSCIENCES INC


15-Apr-2014

Annual Report


ITEM 7. MANAGEMENT DISCUSSION AND ANALYSIS OR PLAN OF OPERATION:

Amended Disclosure Statement for Plan of Reorganization.

The following discussion is the Amended Disclosure Statement for the Plan of Reorganization of Amarillo Biosciences, Inc. (the Company or Debtor or Debtor in Possession). The original Disclosure Statement and Plan of Reorganization were filed on February 21, 2014, in the Bankruptcy Court for the Northern District of Texas. The Disclosure Statement was subsequently amended and filed March 27, 2014 at which time the Amended Disclosure Statement was approved by the Bankruptcy Court. On March 28, 2014, the Order Approving Debtor's Disclosure Statement, Notice of Confirmation Hearing, and Setting Date For Voting and Filing Objections To Confirmation of Debtor's Plan was signed and entered by the United States Bankruptcy Judge.


AMENDED DISCLOSURE STATEMENT FOR PLAN OF REORGANIZATION
(Filed March 27, 2014)

AMARILLO BIOSCIENCES, INC., Debtor and Debtor in Possession ("ABI" or "Debtor"), submits this Amended Disclosure Statement under Chapter 11 of the United States Bankruptcy Code:

1. Introduction

1.01. Debtor provides this Disclosure Statement to Debtor's known creditors and parties in interest pursuant to Section 1125 of the Bankruptcy Code. The purpose of this Disclosure Statement is to provide necessary information for the creditors and Debtor to make a reasonably informed decision in exercising their right to vote for or against acceptance of the Plan of Reorganization ("the Plan") filed on February 21, 2014.

1.02. Except as specifically stated otherwise, all information contained in this Disclosure Statement relating to Debtor has been provided by Debtor or its agents and generated from Debtor's books and records. Projections relating to the future operations of the Reorganized Debtor provided by Debtor are good faith estimates of Debtor. The projections provided by Debtor are based on a number of assumptions that Debtor believes in the aggregate are reasonable. These projections represent only one of a number of scenarios that could be presented to illustrate the future operations of the Reorganized Debtor.

NO REPRESENTATIONS CONCERNING DEBTOR, PARTICULARLY ABOUT FUTURE OPERATIONS OR PROPERTY VALUES, ARE AUTHORIZED BY DEBTOR OTHER THAN AS SET FORTH IN THIS DISCLOSURE STATEMENT. ANY REPRESENTATION OR INDUCEMENT MADE TO SECURE ACCEPTANCE OF THE PLAN, OTHER THAN AS CONTAINED IN THIS DISCLOSURE STATEMENT, SHOULD NOT BE RELIED UPON BY ANY PERSON. THE RECORDS KEPT BY DEBTOR ARE NOT WARRANTED OR REPRESENTED TO BE WITHOUT ANY INACCURACY OR OMISSION, ALTHOUGH EVERY EFFORT HAS BEEN MADE TO MAKE THIS DISCLOSURE STATEMENT ACCURATE AND COMPLETE. THE INFORMATION CONTAINED IN THIS DISCLOSURE STATEMENT HAS NOT BEEN AUDITED OR VERIFIED EXCEPT WHERE SPECIFICALLY STATED, AND ANY EXHIBITS ATTACHED TO THE PLAN AND THE SCHEDULES AND STATEMENTS OF AFFAIRS FILED IN THIS PROCEEDING HAVE LIKEWISE NOT BEEN SUBJECT TO AN AUDIT OR OTHERWISE VERIFIED BY A THIRD PARTY UNLESS SPECIFICALLY STATED. ALL REFERENCES TO ACCOUNT, LOAN, AND CLAIM BALANCES REFERENCED HERE AND ON DEBTOR'S SCHEDULES ARE BASED UPON DEBTOR'S RECORDS, AND THEREFORE, THEY MAY BE SLIGHTLY INACCURATE OR OTHERWISE NOT THE SAME AS BALANCES REFLECTED IN THE CREDITORS' OWN RECORDS. THIS DISCLOSURE STATEMENT HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION NOR HAS THE COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THE STATEMENTS CONTAINED IN THIS STATEMENT.

THIS DISCLOSURE STATEMENT MAY ALSO CONTAIN FORWARD-LOOKING STATEMENTS, WHICH CAN BE IDENTIFIED BT THE USE OF WORDS LIKE "ANTICIPATES," "INTENDS, "BELIEVES," "ESTIMATES," "EXPECTS," OR SIMILAR REFERENCES TO FUTURE PERIODS. ANY MATTERS THAT ARE NOT HISTORICAL FACTS ARE FORWARD-LOOKING, SO THEY MAY INVOLVE ESTIMATES, ASSUMPTIONS, RISKS, AND UNCERTAINTY. ACTUAL RESULTS MAY DIFFER MATERIALLY FROM WHAT MAY BE CONTAINED IN ANY FORWARD-LOOKING STATEMENT.


2. Definitions
1.01. ABI: Amarillo Biosciences, Inc., the Debtor and Debtor in Possession in this case.

1.02. Administrative Expense Claims: Claims that arise from those expenses described in Section 503 of the Bankruptcy Code.

1.03. Affiliates: For purposes of the Plan, "Affiliates" means any entity owned or controlled by the Debtor, together with the Debtor's agents, officers, directors, employees, attorneys, and accountants.

1.04. Allowed Claim: A claim with respect to which: (a) a proof of claim has been filed with the Court on or before the Bar Date, or (b) Debtor has scheduled in a list of creditors prepared and filed with the Court pursuant to Rule 1007, and such claim is not listed as disputed, contingent, or unliquidated as to amount; and in either case, a claim: (i) to which no objection has been timely filed by any party-in-interest, or (ii) that has been allowed by order of the Court that has become final and is no longer subject to appeal.

1.05. Allowed Unsecured Claim of Yang: The unsecured claim of Yang arising from Yang's funding of the continuing operating expenses of Debtor pre-petition, accrued and unpaid obligations of Debtor under the Pre-Petition Credit Documents, and from funding provided pursuant to the Post-Petition Loan Agreement, but excluding the amount of the Allowed Secured Claim of Yang. The Class Two Claim of Yang. 1

1.06. Allowed Priority Claim: An Allowed Claim for which the holder asserts and is determined to be entitled to priority under Section 507, et seq., of the Bankruptcy Code in an amount allowed by final order of the Court. Administrative Expense Claims or Class One Claims.

1.07. Allowed Secured Claim of Yang: An Allowed Secured Claim against Debtor held by Yang, secured by substantially all of Debtor's assets, in particular its tangible and intangible personal property. This claim relates to the secured portion of Debtor's obligations to Yang under the Pre-Petition Credit Documents. The Class Three Claim of Yang.

1.08. Allowed Unsecured Claims of General Trade Creditors: An unsecured Allowed Claim against Debtor that is not an Allowed Priority Claim or an Allowed Unsecured Claim of a creditor in Class Two or Class Five. The Class Four Claims.

1.09. Applicable Federal Rate: The applicable federal rate of interest as determined pursuant to Section 1274(d) of the Internal Revenue Code ("IRC").

1.010. Bankruptcy Code: The United States Bankruptcy Code as codified at 11 U.S.C. § 101, et seq. Text references to statutory code sections refer to the Bankruptcy Code unless otherwise indicated.

1.011. Bankruptcy Court: United States Bankruptcy Court for the Northern District of Texas, Amarillo Division (or a successor court having bankruptcy jurisdiction).

1.012. Bankruptcy Rules: The Federal Rules of Bankruptcy Procedure, and where appropriate, the applicable local rules of the Bankruptcy Court.

1.013. Bar Date: The deadline fixed by the Court as the last day for filing a proof of claim. As of the date of the Plan, that date was set as March 10, 2014 for non-governmental claimants; it was extended for one late-scheduled creditor through April 1, 2014.

1.014. Ballot Deadline: The deadline for submitting ballots to vote to accept or reject the Plan. The Ballot Deadline will be contained in an order of the Bankruptcy Court after approval of the Disclosure Statement. 2


1This does not include claims, if any, that Yang or any Affiliate of Yang may acquire or have acquired from a third party; the Allowed Unsecured Claim of Yang and the Allowed Secured Claim of Yang is limited to funds actually advanced by Yang to ABI.
2 It is anticipated that the order approving a disclosure statement will include a specific date that will serve as the Ballot Deadline


1.015. Cash Contribution: Funds to be paid by Yang upon the Effective Date to Debtor to be used by Debtor to consummate the Plan, including the distributions to the Unsecured Creditors as set forth in the Plan. The Cash Contribution is in the amount of $250,000.00.

1.016. Causes of Action: Causes of action held by Debtor or the Estate against third parties, including Chapter Five Causes of Action.

1.017. Chapter Five Causes of Action. Any claim or action arising under Section 510, 544 - 551 (inclusive), or 553, or otherwise arising under the Bankruptcy Code.

1.018. Common Equity: All issued and outstanding common stock in or to ABI as of October 31, 2013 (73,291,008 issued and outstanding shares).

1.019. Common Equity Security Holders: Holders of any common stock issued prepetition by Debtor. The Class Eight Interest Holders.

1.020. Confirmation: Approval of the Plan by the Court, which shall occur the date upon which the Confirmation Order is entered.

1.021. Confirmation Order: The order of the Court confirming the Plan of Reorganization.

1.022. Consummation: The time when the last act required under the Plan has been completed.

1.023. Debtor: Amarillo Biosciences, Inc. ("ABI"), a Texas corporation whose principal office is in Amarillo, Texas, the Debtor and Debtor-in-Possession ("DIP") in this case.

1.024. Dollars: United States dollars. Any reference to currency or monetary values in the Plan is to United States dollars.

1.025. Effective Date: Twenty-eight (28) days following the entry of the Confirmation Order or such other date as agreed upon by Debtor and Yang following Confirmation.

1.026. Equity Security Holders: The Common Equity Security Holders and the Preferred Equity Security Holders, whenever referenced collectively.

1.027. FINRA: Financial Industry Regulatory Authority; www.finra.org.

1.028. General Unsecured Creditors: Those creditors who hold allowed unsecured claims, other than (and excluding any claim of) Yang.

1.029. Governmental Effective Date: Thirty days following the later of the governmental bar date or the Effective Date.

1.030. Hayashibara: Hayashibara Co., Ltd., of Okayama, Japan, now the purported owner and holder of the HBL Notes.

1.031. HBL: Hayashibara Biochemical Laboratories, Inc., the original holder of the HBL Notes.

1.032. HBL Notes: Two promissory notes, each in the original principal amount of one million each ($1,000,000.00), originally payable to HBL, now purportedly held by Hayashibara.

1.033. IRC: The United States Internal Revenue Code of 1954, as amended, as codified at Title 26, United States Code.

1.034. Insider: Insider is given the meaning set forth under Section 101(31) of the Bankruptcy Code.

1.035. Nagase: Nagase & Co., Ltd. On information and belief, Nagase is an affiliate of Nagase America Corp., and it is the owner or parent company of Hayashibara.

1.036. New ABI: ABI (as of the filing of the Plan, the Debtor) on and after: (i) the Effective Date and (ii) the closing of the reverse stock split and the issuance of new common stock under the Plan.


1.037. Petition Date: The date on which Debtor filed its petition for relief, October 31, 2013.

1.038. Plan: The Plan of Reorganization, including the addendum, attached to and incorporated in the Plan.

1.039. Post-Confirmation Forbearance Agreement: An agreement between Yang and Debtor providing for forbearance on collection of Yang's security interest in the Yang Collateral for a minimum period of twelve months after the Effective Date, consistent with the terms of the Plan.

1.040. Post-Petition Financing Claim: The claim of Yang arising from Yang's funding of the continuing operating expenses of Debtor, pursuant to the Post-Petition Loan Agreement, part of the Allowed Unsecured Claim of Yang.

1.041. Post-Petition Loan Agreement: That certain Loan Agreement entered into by and between Debtor and Yang on December 20, 2013 (effective as of the Petition Date), and approved by the Court in an interim order on December 20, 2013 (Doc. No. 66) and in a final order entered January 15, 2014 (Doc. No. 86).

1.042. Preferred Equity: All issued and outstanding shares of Class 2010-A preferred stock in ABI, being 3,262 shares that are believed held by Tibbits.

1.043. Preferred Equity Security Holders: Holders of any equity securities that have preference rights over general equity securities. The only known Preferred Equity Security Holder is Paul Tibbits, who is believed to hold 3,262 shares out of 10,000 authorized Class 2010-A preferred stock.

1.044. Pre-Petition Credit Documents: The July 19, 2013 Promissory Note from ABI to Yang (renewal of prior debt); the July 25, 2013 Promissory Note from ABI to Yang; the Security Agreement dated July 25, 2013, between ABI and Yang; any other pre-petition documents evidencing the pre-petition claim of Yang.

1.045. Retained Assets: The assets of Debtor that will revest in Debtor on the Effective Date, subject to the Allowed Secured Claim of Yang. The Retained Assets will be and include all assets of Debtor's estate.

1.046. SEC: Securities and Exchange Commission - United States of America.

1.047. Secured Claims: Allowed secured claims of any creditor whose claim is secured by a valid, perfected security interest in pre-petition property of Debtor, other than Yang. The Class Six Claims.

1.048. Tibbits: Paul Tibbits, and to the extent she has any direct or marital property interest, his spouse, Marian Tibbits. According to ABI's records and those of its transfer agent, Tibbits holds in excess of 11,000,000 shares of ABI Common Stock, together with preferred stock that would be converted to common stock under the Plan, if the Plan is confirmed as filed.

1.049. Unclassified Claims: Claims that pursuant to Section 1123(a)(1) of the Bankruptcy Code are not classified and that includes collectively all claims accorded priority pursuant to Sections 507(a)(1), 507(a)(2), and 507(a)(8) of the Code.

1.050. Unsecured Creditors: All Unsecured Creditors, other than Yang, holding unsecured claims that are not Allowed Priority Claims; generally, the Class Four and Class Five Claimants.

1.051. Yang: The Yang Group, Taiwan, is an association, the principal of which is Patrick Ng of Canada. Yang is the creditor holding the Class Two and Class Three Claims and the "secured party" under the Yang Financing Statement.

1.052. Yang Collateral: The assets pledged by Debtor in accordance with the Pre- Petition Credit Documents, including any proceeds, which currently secure the Class Three Secured Claim of Yang.


2. Incorporation of Other Documents; Case Website

This Disclosure Statement incorporates or refers to other documents, including the Debtor's Schedules and Statement of Financial Affairs and monthly operating reports on file with the Clerk of the Bankruptcy Court. Additionally, the Debtor has made various public filings with the Securities and Exchange Commission ("SEC") and the Texas Secretary of State (See Section 3 below). Filings in this bankruptcy case can be viewed at www.upshotservices.com/amarillobiosciences.

3. Background and Basic Financial Information

Background and Company History of Debtor. Amarillo Biosciences, Inc. ("ABI" or "Debtor") is a Texas corporation based in Amarillo, Texas, where its principal office has been located since its inception. ABI's common stock is widely held, as a result of ABI having been a publicly-held company, whose stock has historically been publicly traded. ABI common stock presently trades under the symbol, AMARQ, and its CUSIP is #02301P 10 6.

The Company was incorporated in 1984, under the name "Amarillo Cell Culture Company, Inc." In 1996, the Company completed an initial public offering, and its name was changed to "Amarillo Biosciences, Inc."

Historical Financial Condition. Much of the background and history of the Company is set forth in filings with the Securities and Exchange Commission and the Texas Secretary of State. ABI's most recent SEC filings include a form 10-Q for the quarter ended September 30, 2013, and 8-Ks filed November 1, 2013, February 14, 2014, and February 24, 2014. The form 10-Q is filed on a quarterly basis, and it is likely that another 10-Q will have been filed prior to the hearing on confirmation of the Plan. It is also likely that the 10-K for the year ended 12-31-13 will be filed prior to the hearing on confirmation of the Plan.

ABI files its Annual Report each year under Form 10-K. The Form 10-K and Form10-Q filings reflect substantial information about ABI's historical financial condition, and the reader is encouraged to review these filings.

These and previous filings can be viewed at www.sec.gov or at www.yahoo.brand.edgaronline.com.

Dr. Joseph Cummins was the founding principal of ABI. Dr. Cummins left full-time employment by ABI on November 30, 2012. He was party to a consulting contract as of this bankruptcy filing; that contract is to be rejected under the Plan.

Effective February 22, 2012, Dr. Stephen T. Chen was appointed as Chairman of the Board and Chief Executive Officer (CEO) of ABI.

Description of Business. ABI has been (and is) engaged in the business of biopharmaceutical research and development. Its primary focus historically has been the development of low-dose, orally administered interferon. ABI holds or licenses various patents; it also is the developer of Maxisal®, a dietary supplement to treat dry-mouth symptoms.

Post-confirmation, ABI (referenced as "New ABI" under the Plan) hopes to expand the reach of its research, development, and ultimately marketing of biopharmaceutical, biotechnical, and health related products.

Company Management and Employees. On October 31, 2013, ABI and/or its Affiliates had three employees. Today, ABI has four employees and four directors. The employees include the following persons:

  Stephen  Dr. Chen was named Chairman of the Board in February 2012, and he has
  T. Chen: been a director of the Company since February 1996. He currently
           executes the management functions as not only Chairman, but Chief
           Executive Officer (CEO), President, and Chief Operating Officer. He has
           been President and Chief Executive Officer of STC International, Inc.,
           a health care investment firm, since May 1992. Dr. Chen has over thirty
           years of international business experience, including an extensive
           background in pharmaceutical product acquisition and licensing,
           development of joint venture agreements, execution of business
           strategy, and leadership of start-


up companiesin the pharmaceutical, biotechnology and nutraceutical industries. Dr. Chen has held executive positions in R&D and business development at several major pharmaceutical companies, including Borroughs Wellcome (presently GlaxoSmithKline), Miles Pharmaceuticals (presently Bayer), ICI America (presently AstraZeneca), and Ciba-Geigy (presently Novartis). He received a Ph.D. in Industrial & Physical Pharmacy from Purdue University in 1977.

  Bernard   Chief Financial Officer (CFO). Mr. Cohen holds BBA and MPA degrees
  Cohen:    from West Texas A&M University. He is a long time Amarillo resident
            with over thirty years of management experience. Mr. Cohen has been
            with ABI since October 2009. Mr. Cohen works with Mr. Morris and
            provides reporting necessary for ABI's various SEC filings, and he
            also provides ordinary-course internal bookkeeping and accounting
            services.



  Chrystal    Office manager and administrative support. Ms. Shelton has been with
  Shelton:    ABI since 1987. In addition to handling routine office
              administration, Ms. Shelton is familiar with the form and format of
              SEC filings and interacts with outside professionals who assist ABI
              in its various compliance measures.

Edward L. Secretary and acting general counsel. Mr. Morris practiced law in Morris: Amarillo, Texas, prior to his retirement from full time practice in 2011. His practice included substantial time devoted to corporate and securities law, including services for ABI. Mr. Morris was graduated from Yale College before obtaining his law degree from Harvard Law School.

Directors. The board of directors of ABI consists of the following persons:
Stephen T. Chen, Ph.D., Paul Tibbits, Marian Tibbits, and Yasushi Chikagami.

Bankruptcy. On October 31, 2013, ABI filed for relief under Chapter 11 of the Bankruptcy Code. It remains as Debtor in Possession. ABI has entered into a post-petition financing facility with Yang, which was approved by the Bankruptcy Court in January, 2014. The retention of various professionals necessary to maintain SEC compliance and protection of ABI's intellectual property has been approved.

ABI has retained UpShot Services as a noticing agent for limited noticing services in this case. Upshot Services maintains a website at which the schedules, pleadings, orders, and other information pertaining to this case can be viewed: www.upshotservices.com/amarillobiosciences.

Remaining Assets. ABI holds various patents and related intellectual property, which are described in ABI's schedules. Most, if not all, of ABI's assets secure Yang's claim pursuant to the Pre-Petition Credit Documents. 3

Schedules - Other Assets and Liabilities. Debtor's schedules were filed shortly after the inception of this case. Debtor is the source of the information provided in those schedules; however, creditors and parties-in-interest are referred to Debtor's schedules for further information pertaining to what Debtor believes to be its assets and liabilities.

4. Description of Plan, Means of Execution, and Treatment of Claims and Interests

Reference should be made to the Plan for full details concerning classification and treatment provided for any particular claim or interest. The following is only a summary. The continued existence of ABI would be beneficial given Debtor's history and future opportunities in the area of biotech and biopharmaceutical research and development. Debtor believes that the continued existence of Debtor is in the best interest of the creditors of Debtor because it is unlikely the Unsecured Creditors will receive any distribution unless a Plan of Reorganization is confirmed.


3 ABI also owns office furniture and equipment, which has been fully depreciated and has little resale value


4.01. Summary of Implementation of the Plan. Yang has agreed to fund a Cash

Contribution in the amount of $250,000.00, which will be paid in to ABI upon confirmation and used, for example, to fund the treatment of the Class Four and Five Allowed Claims. In addition, Yang will fund the administrative expenses of Debtor in this bankruptcy proceeding. If the Plan is confirmed, the amount to be paid to each holder of an Allowed Claim in Class Four will be equal to six percent (6%) of the face amount of its Allowed Claim.

4.02. Yang Will Control Reorganized Debtor. In return for forgiveness of the Allowed

Unsecured Claim of Yang and the payment of the Cash Consideration, Yang will receive newly issued stock and effectively own eighty percent (80%) of the ownership interest of Debtor, post-confirmation. The Common Equity Security Holders will undergo a reverse stock split on the basis of one (1) New ABI common share received for every nineteen (19) Old ABI common shares held pre-split, as of a record date to be set by the Directors of ABI pursuant to
Section 6.101(b) of the Texas Business Organizations Code, which date shall be no more than 60 days prior to the implementation of said reverse stock split. The New ABI common shares received pursuant to the reverse split shall not be in addition to, but shall replace, the Old ABI common shares held pre-split, and such Old ABI common shares shall be returned to the status of authorized, but unissued common shares, with the result that the Common Equity Security Holders shall hold, post-reorganization, common stock constituting approximately twenty percent (20%) of the issued and outstanding common stock in the reorganized Debtor, referenced in the Plan as "New ABI." New ABI will continue in the biotech / bio-pharmaceutical / health care products business after the Effective Date.

4.03. Summary of Treatment of Claims. Under the Plan, if confirmed, Allowed Unclassified and Class One claimants are unimpaired and will receive the full value of their claims.

The Class Two Claim, which is the Allowed Unsecured Claim of Yang, which is in excess of $1,216,765.12 (net of Yang's Secured Class Three Claim), will be extinguished in exchange for issuance of common stock constituting eighty percent (80%) of the issued and outstanding common equity of Debtor. 4

Each Class Four claimant who holds an Allowed Claim will receive six percent (6%) of the face amount of its Allowed Claim as a result of the Cash Contribution to be made by Yang; alternatively, such claimant may elect administrative convenience treatment under Class Five.

Based on agreed values between Debtor and Yang, which are substantially higher than liquidation values, Yang will retain a security interest in property, primarily the intangible personal property of ABI (e.g., patents, trademarks, etc.), which is valued for purposes of claim treatment at $150,000.00.

Class Six claimants, if any, will retain their security interest. Debtor believes there are no existing Class Six Claims.

The Equity Interest Holders (Class Seven and Class Eight) will not receive a distribution pursuant to the Plan, and their existing equity interests will be diluted by the reverse stock split and issuance of New ABI stock to Yang as described in paragraph 4.02 above.

5. Classes of Creditors

The following is a list of the various classes of creditors dealt with in the Plan. Reference should be made to the Plan for details concerning the proposed specific treatment of each class.


4 The exact amount of the Allowed Unsecured Claim of Yang, for purposes of Plan treatment is stated in the Plan. The Allowed Unsecured Claim of Yang is based upon, and reflects only amounts that were actually advanced by Yang to ABI (i.e., direct advances and not debt acquired from a third party).


Administrative Expense Claims which are accorded priority pursuant to Section 507(a)(1) and Allowed Priority Claims pursuant to Sections 507(a)(2) and 507(a)(8) are not separately classified.

5.01. Class One: Allowed Priority Claims under Section 507(a)(3) to (a)(7) of the Bankruptcy Code.

5.02. Class Two: Allowed Unsecured Claim of Yang.

5.03. Class Three: Allowed Secured Claim of Yang.

5.04. Class Four: Allowed Unsecured Claims of General Unsecured Creditors.

5.05. Class Five: Administrative Convenience Claims.

5.06. Class Six: Allowed Secured Claims, other than the Secured Claim of Yang.

5.07. Class Seven: The interests of the Preferred Equity Security Holders.

. . .

  Add AMARQ to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for AMARQ - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.